Eyeseryl | CAS#820959-17-9 | hydroscopic moisturizer

MedKoo Cat#: 333202 | Name: Eyeseryl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Eyeseryl, also known as Acetyl Tetrapeptide-5, humectant or hydroscopic moisturizer which helps reduce eye puffiness, improve skin elasticity as well as overall smoothness.

Chemical Structure

Eyeseryl

CAS#820959-17-9

Theoretical Analysis

MedKoo Cat#: 333202

Name: Eyeseryl

CAS#: 820959-17-9

Chemical Formula: C20H28N8O7

Exact Mass: 492.2081

Molecular Weight: 492.49

Elemental Analysis: C, 48.78; H, 5.73; N, 22.75; O, 22.74

Price and Availability

Size	Price	Availability
100mg	USD 250.00	2 Weeks
250mg	USD 450.00	2 Weeks
500mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Ac-beta-ala-his-ser-his-oh; Eyeseryl; Acetyl Tetrapeptide-5; N-Acetyl-beta-alanyl-L-histidyl-L-seryl-L-histidine

IUPAC/Chemical Name

(3-acetamidopropanoyl)-L-histidyl-L-seryl-L-histidine

InChi Key

ROTFCACGLKOUGI-JYJNAYRXSA-N

InChi Code

InChI=1S/C20H28N8O7/c1-11(30)23-3-2-17(31)26-14(4-12-6-21-9-24-12)18(32)28-16(8-29)19(33)27-15(20(34)35)5-13-7-22-10-25-13/h6-7,9-10,14-16,29H,2-5,8H2,1H3,(H,21,24)(H,22,25)(H,23,30)(H,26,31)(H,27,33)(H,28,32)(H,34,35)/t14-,15-,16-/m0/s1

SMILES Code

O=C(NCCC(N[C@@H](CC1=CNC=N1)C(N[C@@H](CO)C(N[C@@H](CC2=CNC=N2)C(O)=O)=O)=O)=O)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 492.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Yarom N, Stewart D, Malik R, Wells J, Avruch L, Jonker DJ. Phase I clinical trial of Exherin (ADH-1) in patients with advanced solid tumors. Curr Clin Pharmacol. 2013 Feb 1;8(1):81-8. PMID: 22280327. 2: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Sep;26(7):587-612. PMID: 15538546. 3: Perotti A, Sessa C, Mancuso A, Noberasco C, Cresta S, Locatelli A, Carcangiu ML, Passera K, Braghetti A, Scaramuzza D, Zanaboni F, Fasolo A, Capri G, Miani M, Peters WP, Gianni L. Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. Ann Oncol. 2009 Apr;20(4):741-5. doi: 10.1093/annonc/mdn695. Epub 2009 Feb 3. PMID: 19190075. 4: Zhuo H, Zhao Y, Cheng X, Xu M, Wang L, Lin L, Lyu Z, Hong X, Cai J. Tumor endothelial cell-derived cadherin-2 promotes angiogenesis and has prognostic significance for lung adenocarcinoma. Mol Cancer. 2019 Mar 4;18(1):34. doi: 10.1186/s12943-019-0987-1. PMID: 30832661; PMCID: PMC6399986. 5: Lammens T, Swerts K, Derycke L, De Craemer A, De Brouwer S, De Preter K, Van Roy N, Vandesompele J, Speleman F, Philippé J, Benoit Y, Beiske K, Bracke M, Laureys G. N-cadherin in neuroblastoma disease: expression and clinical significance. PLoS One. 2012;7(2):e31206. doi: 10.1371/journal.pone.0031206. Epub 2012 Feb 15. PMID: 22355346; PMCID: PMC3280274. 6: Yarom N, Stewart D, Avruch L, Malik R, Wells J, Jonker DJ. ADH-1 in the treatment of metastatic adrenocortical carcinoma--case report. Anticancer Res. 2011 Nov;31(11):3921-5. PMID: 22110220. 7: Blaschuk OW, Devemy E. Cadherins as novel targets for anti-cancer therapy. Eur J Pharmacol. 2009 Dec 25;625(1-3):195-8. doi: 10.1016/j.ejphar.2009.05.033. Epub 2009 Oct 16. PMID: 19836380. 8: Sun Y, Jing J, Xu H, Xu L, Hu H, Tang C, Liu S, Wei Q, Duan R, Guo J, Yang L. N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells. J Immunother Cancer. 2021 Mar;9(3):e002138. doi: 10.1136/jitc-2020-002138. PMID: 33692219; PMCID: PMC7949480. 9: Erez N, Zamir E, Gour BJ, Blaschuk OW, Geiger B. Induction of apoptosis in cultured endothelial cells by a cadherin antagonist peptide: involvement of fibroblast growth factor receptor-mediated signalling. Exp Cell Res. 2004 Apr 1;294(2):366-78. doi: 10.1016/j.yexcr.2003.11.033. PMID: 15023527.